ArticleTransplantation and cellular therapy2026
Excellent Outcomes in Feasibility Study of Radiation-Free Conditioning and Transplant in Pediatric Severe Aplastic Anemia.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Severe aplastic anemia (SAA) is treated with a hematopoietic cell transplant (HCT) in the presence of an HLA-matched sibling donor (MSD) with disease-free survival (DFS) of >90%. In the absence of an MSD, immunosuppressive therapy (IST) can induce remission but concerns for relapsed/refractory disease and clonal hematopoiesis persist. IST failure is an indication for HCT. Modern HCT approaches target barriers such as graft rejection (GR), graft-versus-host disease (GVHD), and transplant-related toxicities. Traditionally, total body irradiation (TBI) inclusive HCT conditioning helps decrease GR, but the use of TBI in children increases concerns for late effects such as malignancies. To describe outcomes after HCT in children with SAA transplanted from the best available donor following a radiation-free RIC regimen in a single-center feasibility trial. The RIC regimen included alemtuzumab, fludarabine, melphalan, ±thiotepa prior to HCT GVHD prophylaxis included tacrolimus, methotrexate, or mycophenolate mofetil. Abatacept was added to GVHD prophylaxis after 2017 to decrease further or eliminate GVHD risk in patients with a non-malignant disorder. This report includes outcomes in 22 consecutive pediatric SAA recipients of HCT (11 MSD, 10 unrelated, and 1 haploidentical) between 2012 and 2023 at a single center. With a median follow-up of 48 months (range, 12-144) all recipients had sustained full myeloid donor chimerism, 100% DFS, and no grade 2 to 4 acute GVHD. One patient (4.5%) developed grade 1 acute skin GVHD, and 1 (4.5%) developed pericardial effusion attributed to chronic GVHD. Complications before day +180 were primarily transient viral reactivations. Thyroid and ovarian hypofunction were the commonest effects noted at long-term follow-up. This radiation-free RIC regimen demonstrated excellent DFS with minimal GVHD in all patients, including those from alternative donor sources. Late complications were primarily endocrine in origin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.